Chengda Pharmaceutical: Pre-disclosure Notice on Shareholders Holding 5% or More of Their Shares Reducing Their Shareholding
Chengda Pharmaceutical: Announcement on the CDE approval of the active ingredient dagliflozin
Chengda Pharmaceutical: Progress Announcement on the Repurchase of the Company\'s Shares
Chengda Pharmaceutical: Announcement on providing guarantees for wholly-owned Sun Company to apply for loans from banks
Chengda Pharmaceutical: Report for the third quarter of 2024
Chengda Pharmaceutical: Announcement of Resolutions of the 10th Meeting of the Fifth Board of Supervisors
Chengda Pharmaceutical: Announcement of Resolutions of the 10th Meeting of the Fifth Board of Directors
Chengda Pharmaceutical: 301201 Chengda Pharmaceutical Research Activity Information 20241023
Chengda Pharmaceutical: Progress Announcement on the Repurchase of the Company\'s Shares
Chengda Pharmaceutical: 301201 Chengda Pharmaceutical Research Activity Information 20240929
Chengda Pharmaceutical: 301201 Chengda Pharmaceutical Research Activity Information 20240926
Chengda Pharmaceutical: Announcement on the repurchase ratio of the company\'s shares reaching 2% and the progress of the repurchase
Chengda Pharmaceutical: Everbright Securities Co., Ltd.\'s 2024 semi-annual follow-up report on Chengda Pharmaceutical Co., Ltd.
Chengda Pharmaceutical: Progress Announcement on the Repurchase of the Company\'s Shares
Chengda Pharmaceutical: 2024 Semi-Annual Report
Chengda Pharmaceutical: Announcement on the Appointment of Deputy General Manager
Chengda Pharmaceutical: Announcement of Board Resolutions
Chengda Pharmaceutical: Announcement of Supervisory Committee Resolutions
Chengda Pharmaceutical: 2024 Semi-Annual Report Summary
Chengda Pharmaceutical: Special Report on the Deposit and Use of Funds Raised for the Semi-Annual Year 2024
No Data
No Data